Gastritis - Pipeline Insight, 2024

This Gastritis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Gastritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastritis Understanding

Gastritis: Overview

Gastritis has its basis in histological features of the gastric mucosa. It is not erythema observed during gastroscopy, and there are no specific clinical presentations or symptoms defining it. The current classification of gastritis centers on time course (acute versus chronic), histological features, anatomic distribution, and underlying pathological mechanisms. Acute gastritis will evolve to chronic, if not treated. Helicobacter pylori (H. pylori) is the most common cause of gastritis worldwide.

H.pylori-associated gastritis transmission is via the fecal-oral route. H. pylori possess several virulence factors which facilitate cell adhesion (e.g., BabA/B, sabA, OipA), cell damage and disruption of tight junctions (e.g., Ure A/B), and evasion from the immune response (e.g. LPS). In particular, the cytotoxin-associated gene a (CagA) is considered a potent inducer of inflammation and correlate with gastric cancer development.

The prognosis depends on the cause. For most people who undertake treatment, the symptoms do decrease but recurrences are common. Patients with H.pylori induced gastritis also have a small risk of developing gastric cancer in future.

Treatment regimens differ from antibiotics (in H. pylori gastritis) to vitamin supplementation (in autoimmune metaplastic atrophic gastritis) to immunomodulatory therapy (in autoimmune enteropathy) to dietary modifications (in eosinophilic gastritis).

Gastritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastritis pipeline landscape is provided which includes the disease overview and Gastritis treatment guidelines. The assessment part of the report embraces, in depth Gastritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Gastritis. The therapies under development are focused on novel approaches to treat/improve Gastritis.
• In June 2021, Neurogastrx announced that it has entered into an exclusive license agreement with Daewoong Pharmaceutical, for the development and commercialization of fexuprazan, an investigational novel potassium-competitive acid blocker (P-CAB) for the treatment of erosive esophagitis (EE) and other acid-related conditions

This segment of the Gastritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastritis Emerging Drugs

Fexuprazan: Daewoong PharmaceuticalFexuprazan is an investigational P-CAB for the treatment of EE, a chronic and progressive condition that impacts millions of patients in the U.S. It is designed to block proton pumps from secreting gastric acid in the stomach. P-CABs have been shown to act more rapidly and suppress the secretion of acid more effectively and more durably than proton pump inhibitors (PPIs), which are the current standard of care for EE.

RHB-102: RedHill BiopharmaRHB-102 is a proprietary, oral, bi-modal extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron. RedHill successfully completed a U.S. Phase 3 study (the GUARD study) with RHB-102 24 mg in patients with acute gastroenteritis and gastritis, meeting the primary efficacy and safety endpoints

Gastritis: Therapeutic Assessment

This segment of the report provides insights about the Gastritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastritis

There are approx. 15+ key companies which are developing the therapies Gastritis. The companies which have their Gastritis drug candidates in the most advanced stage, i.e Phase III include, Hanmi Pharmaceutical.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gastritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastritis drugs.

Gastritis Report Insights

• Gastritis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastritis drugs?
• How many Gastritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daewoong Pharmaceutical
• RedHill Biopharma
• Add Pharma
• Allakos
• Hanmi Pharmaceutical Company Limited
• GC Pharma
• Addpharma

Key Products

• Fexuprazan
• RHB-102
• AD-203
• AD-215
• AK-002
• HIP2101
• DWJ-1366
• GC-6101A
• AD 212
• NT-2150

This product will be delivered within 2 business days.